Article
Dexrazoxane prevents the development of the impaired cardiac phenotype in caveolin-1-disrupted mice.
Journal of cardiovascular pharmacology - 1 Jun 2013
Polanski Anne-Katrin, Ebner Annette, Ebner Bernd, Hofmann Anja, Steinbronn Nadine, Brandt Aljoscha, Forkmann Mathias, Tausche Anne-Kathrin, Morawietz Henning, Strasser Ruth H, Wunderlich Carsten
Abstract excerpt
: Caveolin-1-deficient (cav1) mice display a severely diseased cardiac phenotype with systolic and diastolic heart failure. Accumulating evidence supports a causative role of uncoupled endothelial nitric oxide synthase in the development of these abnormalities. Interestingly, a similar molecular mechanism was proposed for anthracycline-induced cardiomyopathy. Currently, dexrazoxane is approved for the prevention...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
